According to Cognitive Market Research, the global Aflibercept market size will be USD 8787.6 million in 2024. It will expand at a compound annual growth rate (CAGR) of 5.00% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 3515.04 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 2636.28 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 2021.15 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 439.38 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 175.75 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
The Neovascular (Wet) Age-Related Macular Degeneration (AMD) category is the fastest growing segment of the Aflibercept industry
